These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 12590267

  • 1. Anti-spasticity medications.
    Al-Shahrani AM.
    Saudi Med J; 2003 Jan; 24(1):19-22. PubMed ID: 12590267
    [Abstract] [Full Text] [Related]

  • 2. [Treatment of spasticity].
    Autti-Rämö I.
    Duodecim; 1999 Jan; 115(8):877-85. PubMed ID: 11859520
    [No Abstract] [Full Text] [Related]

  • 3. [New therapies for spastic movement disorders].
    Benecke R, Patejdl R.
    MMW Fortschr Med; 2009 Oct; 151 Suppl 3():118-22. PubMed ID: 20623938
    [No Abstract] [Full Text] [Related]

  • 4. Managing spasticity with drugs.
    Simon O, Yelnik AP.
    Eur J Phys Rehabil Med; 2010 Sep; 46(3):401-10. PubMed ID: 20927006
    [Abstract] [Full Text] [Related]

  • 5. The pharmacological management of spasticity.
    Saulino M, Jacobs BW.
    J Neurosci Nurs; 2006 Dec; 38(6):456-9. PubMed ID: 17233517
    [Abstract] [Full Text] [Related]

  • 6. Comparative profile of tizanidine in the management of spasticity.
    Lataste X, Emre M, Davis C, Groves L.
    Neurology; 1994 Nov; 44(11 Suppl 9):S53-9. PubMed ID: 7970011
    [Abstract] [Full Text] [Related]

  • 7. [Tizanidine as treatment of spasticity in patients with hemiplegia caused by a CVA or brain injury].
    Weynants L, Van Laere M.
    Acta Belg Med Phys; 1990 Nov; 13(1):19-22. PubMed ID: 2336897
    [No Abstract] [Full Text] [Related]

  • 8. Anti-spasticity medications.
    Al-Shahrani AM.
    Neurosciences (Riyadh); 2003 Jan; 8(1):8-11. PubMed ID: 23648978
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Botulinum toxin type A with oral baclofen versus oral tizanidine: a nonrandomized pilot comparison in patients with cerebral palsy and spastic equinus foot deformity.
    Dai AI, Wasay M, Awan S.
    J Child Neurol; 2008 Dec; 23(12):1464-6. PubMed ID: 19073853
    [Abstract] [Full Text] [Related]

  • 14. Management of spasticity.
    Ko CK, Ward AB.
    Br J Hosp Med; 2008 Dec; 58(8):400-5. PubMed ID: 9509042
    [Abstract] [Full Text] [Related]

  • 15. Spasticity: revisiting the role and the individual value of several pharmacological treatments.
    Lapeyre E, Kuks JB, Meijler WJ.
    NeuroRehabilitation; 2010 Dec; 27(2):193-200. PubMed ID: 20871149
    [Abstract] [Full Text] [Related]

  • 16. [Current data on bipolar disorders, epilepsy and spasticity. 4. Neuro-Forum, Dresden].
    Fortschr Neurol Psychiatr; 1999 May; 67(5 Suppl Aktuelles):1-12. PubMed ID: 10368778
    [No Abstract] [Full Text] [Related]

  • 17. [Management of spasticity in children with cerebral palsy].
    Matthews DJ, Balaban B.
    Acta Orthop Traumatol Turc; 2009 May; 43(2):81-6. PubMed ID: 19448346
    [Abstract] [Full Text] [Related]

  • 18. Spasticity: a review.
    Young RR.
    Neurology; 1994 Nov; 44(11 Suppl 9):S12-20. PubMed ID: 7970006
    [Abstract] [Full Text] [Related]

  • 19. Pharmacologic treatment of spasticity in children.
    Tilton A, Vargus-Adams J, Delgado MR.
    Semin Pediatr Neurol; 2010 Dec; 17(4):261-7. PubMed ID: 21183133
    [Abstract] [Full Text] [Related]

  • 20. Pharmacotherapy of spasticity: some theoretical and practical considerations.
    Rice GP.
    Can J Neurol Sci; 1987 Aug; 14(3 Suppl):510-2. PubMed ID: 3315153
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.